KG&L Capital Management’s Gilead Sciences GILD Stock Holding History

KG&L Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,842	Closed	-$282K	–	142
2020 Q4	$282K	Buy	4,842 +26	+0.5%	+$1.57K	0.15%	108
2020 Q3	$304K	Buy	+4,816	New	+$334K	0.19%	94
2020 Q1	–	Sell	-7,638	Closed	-$496K	–	92
2019 Q4	$496K	Buy	7,638 +1,868	+32%	+$122K	0.42%	56
2019 Q3	$365K	Sell	5,770 -7,772	-57%	-$508K	0.33%	65
2019 Q2	$914K	Buy	13,542 +2,116	+19%	+$139K	0.87%	35
2019 Q1	$746K	Buy	11,426 +1,191	+12%	+$79.2K	0.75%	40
2018 Q4	$644K	Buy	+10,235	New	+$715K	0.72%	39

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

KG&L Capital Management's GILD Position: Q1 2021 in Review

KG&L Capital Management sold out of Gilead Sciences (GILD) in Q1 2021, closing a stake of 4,842 shares — an estimated $282K sold.

KG&L Capital Management first reported a position in GILD in Q4 2018 and held it in 7 quarters. The position peaked at $914K in Q2 2019. 1,567 funds tracked by Wall St. Rank hold GILD as of Q1 2021.

KG&L Capital Management reported no remaining Gilead Sciences position as of Q1 2021 after selling out during the quarter.
KG&L Capital Management sold 4,842 Gilead Sciences shares in Q1 2021, an estimated $282K.
KG&L Capital Management first reported a position in Gilead Sciences in Q4 2018 and held it in 7 quarters.
KG&L Capital Management's Gilead Sciences position peaked at $914K in Q2 2019.
1,567 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2021.

Based on KG&L Capital Management's 13F filing for Q1 2021, filed 14 Apr 2021.